Made byBobr AI

Hyperemesis Gravidarum: Diagnosis and Management Guide

A clinical overview of Hyperemesis Gravidarum (HG) covering pathophysiology, GDF15 research, PUQE scoring, and stepwise treatment for medical professionals.

#hyperemesis-gravidarum#obgyn-lecture#pregnancy-complications#medical-education#pathophysiology#maternal-health#clinical-guidelines#gdf15
Watch
Pitch
OB/GYN

HYPEREMESIS
GRAVIDARUM

Pathophysiology, Diagnosis & Management

A Clinical Overview for Medical Students & Residents

Prevalence: 0.3–3% of Pregnancies | Leading Cause of Early Hospitalization

Made byBobr AI
DEFINITION

What is Hyperemesis Gravidarum?

Severe, intractable nausea and vomiting of pregnancy causing ≥5% pre-pregnancy weight loss, dehydration, and electrolyte imbalances.

Feature
MORNING SICKNESS
HYPEREMESIS GRAVIDARUM
Prevalence
50–80%
0.3–3%
Weight loss
None / <5%
≥5%
Hospitalization
Rarely
Often required
Resolution
Usually by 12–14 wks
May persist all pregnancy
Ketonuria
Absent
Present

ONSET

4–6 weeks gestation

PEAK

8–12 weeks gestation

PERSISTENCE

Beyond 20 weeks in ~20% of cases

No universal diagnostic criteria — PUQE score used to quantify severity.

HG is NOT just 'bad morning sickness' — it is a serious medical condition requiring clinical intervention.

Made byBobr AI
EPIDEMIOLOGY

Epidemiology & Risk Factors

0.3–3%
Global prevalence of pregnancies affected
#2
Leading cause of hospitalization in early pregnancy (after preterm labor)
24%
Recurrence rate in subsequent pregnancies
3x
Increased risk with family history (maternal)
$3B+
Annual cost burden in the United States

Known Risk Factors

Multiple gestation (twins, triplets)
Molar pregnancy
Female fetal sex
Prior history of HG
Family history (mother or sister)
History of motion sickness or migraines
H. pylori infection
Low pre-pregnancy GDF15 levels (genetic)
Age <24 years
Lower socioeconomic status

Incidence may be underestimated due to inconsistent diagnostic criteria across studies.

Made byBobr AI
PATHOPHYSIOLOGY

Pathophysiology

GDF15 & Genetic Factors

  • GDF15 from fetal-placental unit
  • Acts on GFRAL receptor in area postrema
  • Low maternal pre-preg GDF15 = hypersensitivity
  • Variants in GDF15, PGR, IGFBP7 genes

Brainstem-Mediated Nausea & Vomiting

Hormonal Factors

  • hCG surge (peaks 8–12 wks)
  • Estrogen elevation
  • Progesterone → reduced GI motility
  • Gestational thyrotoxicosis (↑ fT4, ↓ TSH)

Other Contributors

  • H. pylori infection
  • Autonomic nervous system dysregulation
  • Psychosocial amplification
  • GI dysmotility

KEY INSIGHT — GDF15 is NOW considered the primary driver — maternal sensitivity to fetal GDF15 surge is the leading mechanistic hypothesis (2024–2026 research).

Made byBobr AI
Diagnosis

Clinical Features & Diagnosis

Clinical Features

Nausea and vomiting >3x/day
≥5% loss of pre-pregnancy weight
Dehydration (dry mucosa, orthostasis)
Ketonuria (≥2+)
Fatigue and weakness
Ptyalism (excessive salivation)
Inability to tolerate oral intake

Investigations

Electrolytes Hyponatremia, Hypokalemia, Hypochloremia
Urine Ketones ≥2+, raised specific gravity
LFTs Elevated up to 3× normal
TSH / T4 Transient thyrotoxicosis
BUN / Cr Elevated
Ultrasound Rule out molar pregnancy / multiples

PUQE Score

Pregnancy-Unique Quantification of Emesis

Assesses over the past 24 hours: hours of nausea, episodes of vomiting, episodes of retching.

Score ≤6 Mild
Score 7–12 Moderate
Score ≥13 Severe

Score ≥7 = consider hospitalization

Differential Diagnosis: Gastroenteritis, GERD, Peptic ulcer, Appendicitis, Pancreatitis, UTI, Thyroid disease | Must be excluded.

Made byBobr AI
COMPLICATIONS

Complications of Hyperemesis Gravidarum

Maternal Complications

Wernicke's Encephalopathy

Thiamine (B1) deficiency; triad: confusion, ophthalmoplegia, ataxia

Mallory-Weiss Tears

Esophageal mucosal tears from forceful vomiting

Electrolyte Imbalances

Hypokalemia → arrhythmias; hyponatremia → seizures

Splenic Avulsion / Rupture

Rare but life-threatening internal injuries

Muscle Wasting & Malnutrition

Severe cases requiring enteral/parenteral nutrition

Psychological Impact

Depression, anxiety, PTSD in 83% of patients

Fetal / Neonatal Complications

1.5×
Increased risk of ADHD / autism spectrum disorder
Low birth weight & preterm birth risk (severe, untreated HG)
Neurodevelopmental concerns in offspring

Wernicke's Encephalopathy is PREVENTABLE — thiamine supplementation is mandatory before IV dextrose administration.

Made byBobr AI
MANAGEMENT

Management: A Stepwise Approach

STEP 1

Lifestyle & Non-Pharmacological

  • Small frequent meals, avoid triggers
  • Ginger 1g/day
    (Level A evidence)
  • P6 acupressure (wristbands)
  • Rest, avoid strong smells
  • Emotional support & reassurance
STEP 2

First-Line Pharmacotherapy

  • Pyridoxine (Vitamin B6) 10–25mg QID
  • + Doxylamine 10–25mg
  • Antihistamines:
    dimenhydrinate, promethazine
  • Oral/IV hydration if tolerated
STEP 3

Second-Line: IV Therapy & Antiemetics

  • IV fluids: Lactated Ringer's 2L initial bolus
  • Thiamine 100–500mg IV
    BEFORE glucose
  • Ondansetron 4–8mg IV q8h
  • Metoclopramide 10mg IV/IM
  • Correct electrolyte imbalances
STEP 4

Refractory / Severe

  • Corticosteroids (methylprednisolone)
    Short term, avoid <10 weeks
  • Mirtazapine (off-label)
  • Enteral nutrition (NG/NJ tube)
  • Total parenteral nutrition (TPN)
    Last resort

Follow ACOG/RCOG 2024 guidelines — avoid withholding treatment due to unfounded teratogenicity concerns.

Made byBobr AI
PHARMACOLOGY

ANTIEMETIC DRUG SUMMARY

Drug Class Dose Route Safety (Cat/Notes)
Pyridoxine (B6) Vitamin 10–25mg QID PO
Safe (FDA Cat A)
Doxylamine Antihistamine 10–25mg QID PO
Safe (FDA Cat A) — Diclegis combo
Promethazine Phenothiazine 25mg q4–6h PO/IV/PR
Cat C — sedating
Dimenhydrinate Antihistamine 50–100mg q4–6h PO/IV
Cat B
Metoclopramide Dopamine antagonist 10mg q6–8h PO/IV
Cat B — EPS risk
Ondansetron 5-HT3 antagonist 4–8mg q8h PO/IV
Cat B — use >10 wks; QTc monitoring
Methylprednisolone Corticosteroid 16mg q8h × 3 days IV/PO
Avoid <10 wks (cleft palate risk)
Mirtazapine NaSSA antidepressant 15–30mg/day PO
Off-label; refractory cases
Thiamine (B1) Vitamin 100–500mg/day IV
Mandatory before IV dextrose

Ondansetron: Avoid in first trimester if possible — associated with small risk of cardiac septal defects and cleft palate.

Always give Thiamine BEFORE glucose/dextrose to prevent Wernicke's Encephalopathy.

Made byBobr AI
NUTRITION

NUTRITIONAL SUPPORT & INPATIENT CARE

Indications for Hospitalization

Failed outpatient management

Inability to tolerate ANY oral intake

>5% weight loss from pre-pregnancy weight

Severe electrolyte abnormalities

Ketonuria ≥2+ with dehydration signs

Orthostatic hypotension

Altered mental status (concern for Wernicke's)

Nutritional Escalation Ladder

Oral Refeeding

Stage 1

Small frequent meals, bland foods, oral rehydration, ginger, B6. Restart slowly after IV stabilization.

Enteral Nutrition

Stage 2

NG or NJ tube feeding. Preferred over parenteral. Continuous feeds tolerated better. Monitor for refeeding syndrome.

Total Parenteral Nutrition (TPN)

Last Resort

Last resort. Reserved for failure of enteral feeding. High risk: infection, thrombosis, liver disease. Requires central venous access.

Refeeding Syndrome Risk: Monitor phosphate, magnesium, potassium when reintroducing nutrition after prolonged starvation.

Made byBobr AI
PSYCHOSOCIAL

Psychosocial Impact

83%
of HG patients report significant
psychosocial impacts
Up to 50%
experience depression
and anxiety
PTSD
documented in a subset of
severe HG patients

Psychological Burden

  • Fear of eating and drinking
  • Social isolation & inability to work
  • Pregnancy termination considered in severe cases (15%)
  • Partner and family strain
  • Feelings of guilt & being misunderstood by HCPs

Supportive Care Strategies

  • Validate patient experience — HG is NOT psychological in origin
  • Refer to perinatal mental health services
  • Connect with HER Foundation & patient support networks
  • Flexible work/sick leave documentation
  • Shared decision-making with patient

HG has a profound psychological toll — compassionate, non-dismissive communication is part of treatment.

Made byBobr AI
RESEARCH

Emerging Research & Future Directions

Recent Discoveries (2024–2026)

GDF15 confirmed as primary causal driver — fetal-placental origin

GFRAL receptor in brainstem area postrema identified as key target

10 genes associated with HG identified (USC 2026 study) — 6 are newly discovered

Low pre-pregnancy GDF15 = hypersensitivity hypothesis

Pre-pregnancy metformin pre-conditioning may reduce GDF15 sensitivity

Rising recognition of child neurodevelopmental outcomes (ADHD, autism 1.5× risk)

Clinical Trials & Pipeline

01
NGM120 — GDF15 Blocker
Phase 2 trial in UK & Australia (2025); results expected 2026. Targets GFRAL receptor to block nausea signal.
02
Metformin Pre-treatment
Hypothesis: raise baseline GDF15 pre-pregnancy to reduce sensitivity. Early-stage investigation.
03
Psychological Intervention Trials
CBT and perinatal mental health integration for HG patients.
04
RCOG Green-Top 2024 Update
New guidance on NVP/HG management in England.

The future of HG treatment may lie in hormonal sensitization — not just symptom suppression.

Made byBobr AI
SUMMARY

KEY TAKEAWAYS

1

HG ≠ Morning Sickness

A serious condition with ≥5% weight loss, dehydration, and hospitalization risk.

2

Onset 4–6 wks, peaks 8–12 wks

May persist beyond 20 weeks in 1 in 5 patients.

3

GDF15 is the key driver

Fetal-placental GDF15 acting on brainstem GFRAL receptors; low maternal baseline = hypersensitivity.

4

Diagnose clinically

Use PUQE score; exclude differentials; check electrolytes, LFTs, TSH, urine ketones.

5

Stepwise management

Lifestyle → B6/doxylamine → IV fluids + thiamine → ondansetron → enteral nutrition → TPN.

6

Always give thiamine FIRST

Before any IV dextrose to prevent Wernicke's encephalopathy.

7

Don't underestimate psychosocial burden

83% of patients affected; validate symptoms, refer to mental health.

8

Watch the pipeline

GDF15 blocker (NGM120) in trials; genetic research reshaping our understanding.

Hyperemesis Gravidarum is a serious, evidence-based diagnosis — early recognition and treatment saves lives.

Made byBobr AI
Bobr AI

DESIGNER-MADE
PRESENTATION,
GENERATED FROM
YOUR PROMPT

Create your own professional slide deck with real images, data charts, and unique design in under a minute.

Generate For Free

Hyperemesis Gravidarum: Diagnosis and Management Guide

A clinical overview of Hyperemesis Gravidarum (HG) covering pathophysiology, GDF15 research, PUQE scoring, and stepwise treatment for medical professionals.

OB/GYN

HYPEREMESIS<br>GRAVIDARUM

Pathophysiology, Diagnosis & Management

A Clinical Overview for Medical Students & Residents

Prevalence: 0.3–3% of Pregnancies <span style="font-weight: 300; margin: 0 15px; color: #74C69D;">|</span> Leading Cause of Early Hospitalization

DEFINITION

What is Hyperemesis Gravidarum?

Severe, intractable nausea and vomiting of pregnancy causing ≥5% pre-pregnancy weight loss, dehydration, and electrolyte imbalances.

<div style="display: flex; align-items: center; flex: 1; border-bottom: 1px solid #E9ECEF;"> <div style="flex: 1.1; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 600; color: #495057;">Prevalence</div> <div style="flex: 1.3; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 400; color: #4A4A4A; text-align: center;">50–80%</div> <div style="flex: 1.4; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 700; color: #1B4332; text-align: center; background-color: rgba(116,198,157,0.15); border-radius: 8px; padding: 12px 0;">0.3–3%</div> </div> <div style="display: flex; align-items: center; flex: 1; border-bottom: 1px solid #E9ECEF;"> <div style="flex: 1.1; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 600; color: #495057;">Weight loss</div> <div style="flex: 1.3; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 400; color: #4A4A4A; text-align: center;">None / &lt;5%</div> <div style="flex: 1.4; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 700; color: #1B4332; text-align: center; background-color: rgba(116,198,157,0.15); border-radius: 8px; padding: 12px 0;">≥5%</div> </div> <div style="display: flex; align-items: center; flex: 1; border-bottom: 1px solid #E9ECEF;"> <div style="flex: 1.1; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 600; color: #495057;">Hospitalization</div> <div style="flex: 1.3; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 400; color: #4A4A4A; text-align: center;">Rarely</div> <div style="flex: 1.4; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 700; color: #1B4332; text-align: center; background-color: rgba(116,198,157,0.15); border-radius: 8px; padding: 12px 0;">Often required</div> </div> <div style="display: flex; align-items: center; flex: 1; border-bottom: 1px solid #E9ECEF;"> <div style="flex: 1.1; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 600; color: #495057;">Resolution</div> <div style="flex: 1.3; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 400; color: #4A4A4A; text-align: center;">Usually by 12–14 wks</div> <div style="flex: 1.4; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 700; color: #1B4332; text-align: center; background-color: rgba(116,198,157,0.15); border-radius: 8px; padding: 12px 0;">May persist all pregnancy</div> </div> <div style="display: flex; align-items: center; flex: 1;"> <div style="flex: 1.1; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 600; color: #495057;">Ketonuria</div> <div style="flex: 1.3; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 400; color: #4A4A4A; text-align: center;">Absent</div> <div style="flex: 1.4; font-family: 'Inter', sans-serif; font-size: 24px; font-weight: 700; color: #1B4332; text-align: center; background-color: rgba(116,198,157,0.15); border-radius: 8px; padding: 12px 0;">Present</div> </div>

<div style="background-color: white; border: 1px solid #E9ECEF; border-left: 8px solid #74C69D; border-radius: 12px; padding: 30px 40px; box-shadow: 0 10px 25px rgba(0,0,0,0.03); box-sizing: border-box;"> <p style="font-family: 'Barlow Condensed', sans-serif; font-size: 26px; font-weight: 700; color: #74C69D; margin: 0 0 5px 0; text-transform: uppercase; letter-spacing: 1px;">ONSET</p> <p style="font-family: 'Inter', sans-serif; font-size: 32px; font-weight: 600; color: #1B4332; margin: 0;">4–6 weeks gestation</p> </div> <div style="background-color: white; border: 1px solid #E9ECEF; border-left: 8px solid #74C69D; border-radius: 12px; padding: 30px 40px; box-shadow: 0 10px 25px rgba(0,0,0,0.03); box-sizing: border-box;"> <p style="font-family: 'Barlow Condensed', sans-serif; font-size: 26px; font-weight: 700; color: #74C69D; margin: 0 0 5px 0; text-transform: uppercase; letter-spacing: 1px;">PEAK</p> <p style="font-family: 'Inter', sans-serif; font-size: 32px; font-weight: 600; color: #1B4332; margin: 0;">8–12 weeks gestation</p> </div> <div style="background-color: white; border: 1px solid #E9ECEF; border-left: 8px solid #74C69D; border-radius: 12px; padding: 30px 40px; box-shadow: 0 10px 25px rgba(0,0,0,0.03); box-sizing: border-box;"> <p style="font-family: 'Barlow Condensed', sans-serif; font-size: 26px; font-weight: 700; color: #74C69D; margin: 0 0 5px 0; text-transform: uppercase; letter-spacing: 1px;">PERSISTENCE</p> <p style="font-family: 'Inter', sans-serif; font-size: 32px; font-weight: 600; color: #1B4332; margin: 0;">Beyond 20 weeks in ~20% of cases</p> </div>

<strong style="color: #E63946;">No universal diagnostic criteria</strong> — PUQE score used to quantify severity.

HG is <span style="color: #74C69D;">NOT</span> just 'bad morning sickness' — it is a serious medical condition requiring clinical intervention.

EPIDEMIOLOGY

Epidemiology & Risk Factors

0.3–3%

Global prevalence of pregnancies affected

#2

Leading cause of hospitalization in early pregnancy (after preterm labor)

24%

Recurrence rate in subsequent pregnancies

3x

Increased risk with family history (maternal)

$3B+

Annual cost burden in the United States

Known Risk Factors

Multiple gestation (twins, triplets)

Molar pregnancy

Female fetal sex

Prior history of HG

Family history (mother or sister)

History of motion sickness or migraines

H. pylori infection

Low pre-pregnancy GDF15 levels (genetic)

Age &lt;24 years

Lower socioeconomic status

Incidence may be underestimated due to inconsistent diagnostic criteria across studies.

PATHOPHYSIOLOGY

Pathophysiology

Brainstem-Mediated Nausea & Vomiting

GDF15 & Genetic Factors

<ul style="margin: 0; padding-left: 20px;"><li style="margin-bottom: 8px;">GDF15 from fetal-placental unit</li><li style="margin-bottom: 8px;">Acts on GFRAL receptor in area postrema</li><li style="margin-bottom: 8px;">Low maternal pre-preg GDF15 = hypersensitivity</li><li style="margin-bottom: 8px;">Variants in GDF15, PGR, IGFBP7 genes</li></ul>

Hormonal Factors

<ul style="margin: 0; padding-left: 20px;"><li style="margin-bottom: 8px;">hCG surge (peaks 8–12 wks)</li><li style="margin-bottom: 8px;">Estrogen elevation</li><li style="margin-bottom: 8px;">Progesterone &rarr; reduced GI motility</li><li style="margin-bottom: 8px;">Gestational thyrotoxicosis (&uarr; fT4, &darr; TSH)</li></ul>

Other Contributors

<ul style="margin: 0; padding-left: 20px;"><li style="margin-bottom: 8px;">H. pylori infection</li><li style="margin-bottom: 8px;">Autonomic nervous system dysregulation</li><li style="margin-bottom: 8px;">Psychosocial amplification</li><li style="margin-bottom: 8px;">GI dysmotility</li></ul>

GDF15 is <strong style="color: #1B4332; font-weight: 700;">NOW</strong> considered the primary driver — maternal sensitivity to fetal GDF15 surge is the leading mechanistic hypothesis (2024–2026 research).

Diagnosis

Clinical Features & Diagnosis

<div style="display: flex; align-items: flex-start; gap: 15px;"> <svg style="width: 24px; height: 24px; flex-shrink: 0; margin-top: 1px; color: #74C69D;" fill="none" stroke="currentColor" stroke-width="3" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7"></path></svg> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #343A40; line-height: 1.4; font-weight: 500;">Nausea and vomiting >3x/day</span> </div> <div style="display: flex; align-items: flex-start; gap: 15px;"> <svg style="width: 24px; height: 24px; flex-shrink: 0; margin-top: 1px; color: #74C69D;" fill="none" stroke="currentColor" stroke-width="3" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7"></path></svg> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #343A40; line-height: 1.4; font-weight: 500;">≥5% loss of pre-pregnancy weight</span> </div> <div style="display: flex; align-items: flex-start; gap: 15px;"> <svg style="width: 24px; height: 24px; flex-shrink: 0; margin-top: 1px; color: #74C69D;" fill="none" stroke="currentColor" stroke-width="3" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7"></path></svg> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #343A40; line-height: 1.4; font-weight: 500;">Dehydration (dry mucosa, orthostasis)</span> </div> <div style="display: flex; align-items: flex-start; gap: 15px;"> <svg style="width: 24px; height: 24px; flex-shrink: 0; margin-top: 1px; color: #74C69D;" fill="none" stroke="currentColor" stroke-width="3" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7"></path></svg> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #343A40; line-height: 1.4; font-weight: 500;">Ketonuria (≥2+)</span> </div> <div style="display: flex; align-items: flex-start; gap: 15px;"> <svg style="width: 24px; height: 24px; flex-shrink: 0; margin-top: 1px; color: #74C69D;" fill="none" stroke="currentColor" stroke-width="3" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7"></path></svg> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #343A40; line-height: 1.4; font-weight: 500;">Fatigue and weakness</span> </div> <div style="display: flex; align-items: flex-start; gap: 15px;"> <svg style="width: 24px; height: 24px; flex-shrink: 0; margin-top: 1px; color: #74C69D;" fill="none" stroke="currentColor" stroke-width="3" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7"></path></svg> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #343A40; line-height: 1.4; font-weight: 500;">Ptyalism (excessive salivation)</span> </div> <div style="display: flex; align-items: flex-start; gap: 15px;"> <svg style="width: 24px; height: 24px; flex-shrink: 0; margin-top: 1px; color: #74C69D;" fill="none" stroke="currentColor" stroke-width="3" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" d="M5 13l4 4L19 7"></path></svg> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #343A40; line-height: 1.4; font-weight: 500;">Inability to tolerate oral intake</span> </div>

<div style="display: flex; justify-content: space-between; border-bottom: 2px solid #F1F3F5; padding-bottom: 12px;"> <span style="font-family: 'Inter', sans-serif; font-size: 20px; font-weight: 700; color: #1B4332; width: 38%;">Electrolytes</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; width: 58%; line-height: 1.3;">Hyponatremia, Hypokalemia, Hypochloremia</span> </div> <div style="display: flex; justify-content: space-between; border-bottom: 2px solid #F1F3F5; padding-bottom: 12px;"> <span style="font-family: 'Inter', sans-serif; font-size: 20px; font-weight: 700; color: #1B4332; width: 38%;">Urine</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; width: 58%; line-height: 1.3;">Ketones ≥2+, raised specific gravity</span> </div> <div style="display: flex; justify-content: space-between; border-bottom: 2px solid #F1F3F5; padding-bottom: 12px;"> <span style="font-family: 'Inter', sans-serif; font-size: 20px; font-weight: 700; color: #1B4332; width: 38%;">LFTs</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; width: 58%; line-height: 1.3;">Elevated up to 3× normal</span> </div> <div style="display: flex; justify-content: space-between; border-bottom: 2px solid #F1F3F5; padding-bottom: 12px;"> <span style="font-family: 'Inter', sans-serif; font-size: 20px; font-weight: 700; color: #1B4332; width: 38%;">TSH / T4</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; width: 58%; line-height: 1.3;">Transient thyrotoxicosis</span> </div> <div style="display: flex; justify-content: space-between; border-bottom: 2px solid #F1F3F5; padding-bottom: 12px;"> <span style="font-family: 'Inter', sans-serif; font-size: 20px; font-weight: 700; color: #1B4332; width: 38%;">BUN / Cr</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; width: 58%; line-height: 1.3;">Elevated</span> </div> <div style="display: flex; justify-content: space-between; padding-top: 4px;"> <span style="font-family: 'Inter', sans-serif; font-size: 20px; font-weight: 700; color: #1B4332; width: 38%;">Ultrasound</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; width: 58%; line-height: 1.3;">Rule out molar pregnancy / multiples</span> </div>

<p style="font-family: 'Inter', sans-serif; font-size: 20px; font-weight: 700; color: #1B4332; margin: 0 0 6px 0;">Pregnancy-Unique Quantification of Emesis</p> <p style="font-family: 'Inter', sans-serif; font-size: 19px; color: #495057; margin: 0; line-height: 1.5;">Assesses over the past 24 hours: hours of nausea, episodes of vomiting, episodes of retching.</p>

<div style="display: flex; align-items: center; justify-content: space-between; padding: 14px 20px; background-color: #F8F9FA; border-radius: 8px; border-left: 5px solid #74C69D;"> <span style="font-family: 'Inter', sans-serif; font-size: 22px; font-weight: 700; color: #1B4332;">Score ≤6</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; font-weight: 600;">Mild</span> </div> <div style="display: flex; align-items: center; justify-content: space-between; padding: 14px 20px; background-color: #F8F9FA; border-radius: 8px; border-left: 5px solid #F4A261;"> <span style="font-family: 'Inter', sans-serif; font-size: 22px; font-weight: 700; color: #1B4332;">Score 7–12</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; font-weight: 600;">Moderate</span> </div> <div style="display: flex; align-items: center; justify-content: space-between; padding: 14px 20px; background-color: #F8F9FA; border-radius: 8px; border-left: 5px solid #E63946;"> <span style="font-family: 'Inter', sans-serif; font-size: 22px; font-weight: 700; color: #1B4332;">Score ≥13</span> <span style="font-family: 'Inter', sans-serif; font-size: 20px; color: #495057; font-weight: 600;">Severe</span> </div>

Score ≥7 = consider hospitalization

Gastroenteritis, GERD, Peptic ulcer, Appendicitis, Pancreatitis, UTI, Thyroid disease <span style="font-weight: 300; margin: 0 15px; color: rgba(255,255,255,0.4);">|</span> <span style="font-weight: 400; color: #E9ECEF;">Must be excluded.</span>

COMPLICATIONS

Complications of Hyperemesis Gravidarum

Maternal Complications

Wernicke's Encephalopathy

Thiamine (B1) deficiency; triad: confusion, ophthalmoplegia, ataxia

Mallory-Weiss Tears

Esophageal mucosal tears from forceful vomiting

Electrolyte Imbalances

Hypokalemia → arrhythmias; hyponatremia → seizures

Splenic Avulsion / Rupture

Rare but life-threatening internal injuries

Muscle Wasting & Malnutrition

Severe cases requiring enteral/parenteral nutrition

Psychological Impact

Depression, anxiety, PTSD in 83% of patients

Fetal / Neonatal Complications

Increased risk of ADHD / autism spectrum disorder

Low birth weight & preterm birth risk (severe, untreated HG)

Neurodevelopmental concerns in offspring

MANAGEMENT

Management: A Stepwise Approach

Lifestyle & Non-Pharmacological

<ul style="list-style: none; margin: 0; padding: 0;"> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #40916C;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Small frequent meals, avoid triggers </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #40916C;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Ginger 1g/day <br><span style="font-weight: 400; opacity: 0.8; font-size: 18px;">(Level A evidence)</span> </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #40916C;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> P6 acupressure <span style="font-weight: 400; opacity: 0.8; font-size: 18px;">(wristbands)</span> </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #40916C;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Rest, avoid strong smells </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #40916C;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Emotional support & reassurance </li> </ul>

First-Line Pharmacotherapy

<ul style="list-style: none; margin: 0; padding: 0;"> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #1B4332;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Pyridoxine <span style="font-weight: 400; opacity: 0.8; font-size: 18px;">(Vitamin B6)</span> 10–25mg QID </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #1B4332;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> + Doxylamine 10–25mg </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #1B4332;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Antihistamines:<br><span style="font-weight: 400; font-size: 18px; opacity: 0.9;">dimenhydrinate, promethazine</span> </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #1B4332;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Oral/IV hydration if tolerated </li> </ul>

Second-Line: IV Therapy & Antiemetics

<ul style="list-style: none; margin: 0; padding: 0;"> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #B7E4C7;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>IV fluids:</strong> Lactated Ringer's 2L initial bolus </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #B7E4C7;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>Thiamine</strong> 100–500mg IV <br><em style="font-style: italic; opacity: 0.9; font-size: 18px;">BEFORE glucose</em> </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #B7E4C7;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>Ondansetron</strong> 4–8mg IV q8h </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #B7E4C7;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>Metoclopramide</strong> 10mg IV/IM </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #B7E4C7;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> Correct electrolyte imbalances </li> </ul>

Refractory / Severe

<ul style="list-style: none; margin: 0; padding: 0;"> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #74C69D;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>Corticosteroids</strong> (methylprednisolone)<br><span style="opacity: 0.8; font-size: 18px;">Short term, avoid &lt;10 weeks</span> </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #74C69D;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>Mirtazapine</strong> (off-label) </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #74C69D;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>Enteral nutrition</strong> (NG/NJ tube) </li> <li style="position: relative; padding-left: 32px; margin-bottom: 14px;"> <svg style="position: absolute; left: 0; top: 5px; color: #74C69D;" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="3" stroke-linecap="round" stroke-linejoin="round"><polyline points="9 18 15 12 9 6"></polyline></svg> <strong>Total parenteral nutrition (TPN)</strong><br><span style="opacity: 0.8; font-size: 18px;">Last resort</span> </li> </ul>

Follow <strong>ACOG/RCOG 2024 guidelines</strong> — avoid withholding treatment due to unfounded teratogenicity concerns.

PHARMACOLOGY

ANTIEMETIC DRUG SUMMARY

<tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #FFFFFF;"> <td style="padding: 13px 24px; font-weight: 700;">Pyridoxine (B6)</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">Vitamin</td> <td style="padding: 13px 24px; font-weight: 500;">10–25mg QID</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">PO</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #52B788; flex-shrink: 0;"></span> <span>Safe (FDA Cat A)</span> </div> </td> </tr> <tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #F8FAF7;"> <td style="padding: 13px 24px; font-weight: 700;">Doxylamine</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">Antihistamine</td> <td style="padding: 13px 24px; font-weight: 500;">10–25mg QID</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">PO</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #52B788; flex-shrink: 0;"></span> <span>Safe (FDA Cat A) — Diclegis combo</span> </div> </td> </tr> <tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #FFFFFF;"> <td style="padding: 13px 24px; font-weight: 700;">Promethazine</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">Phenothiazine</td> <td style="padding: 13px 24px; font-weight: 500;">25mg q4–6h</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">PO/IV/PR</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #F4A261; flex-shrink: 0;"></span> <span>Cat C — sedating</span> </div> </td> </tr> <tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #F8FAF7;"> <td style="padding: 13px 24px; font-weight: 700;">Dimenhydrinate</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">Antihistamine</td> <td style="padding: 13px 24px; font-weight: 500;">50–100mg q4–6h</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">PO/IV</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #E9C46A; flex-shrink: 0;"></span> <span>Cat B</span> </div> </td> </tr> <tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #FFFFFF;"> <td style="padding: 13px 24px; font-weight: 700;">Metoclopramide</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">Dopamine antagonist</td> <td style="padding: 13px 24px; font-weight: 500;">10mg q6–8h</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">PO/IV</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #E9C46A; flex-shrink: 0;"></span> <span>Cat B — EPS risk</span> </div> </td> </tr> <tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #F8FAF7;"> <td style="padding: 13px 24px; font-weight: 700;">Ondansetron</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">5-HT3 antagonist</td> <td style="padding: 13px 24px; font-weight: 500;">4–8mg q8h</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">PO/IV</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #E9C46A; flex-shrink: 0;"></span> <span>Cat B — use &gt;10 wks; QTc monitoring</span> </div> </td> </tr> <tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #FFFFFF;"> <td style="padding: 13px 24px; font-weight: 700;">Methylprednisolone</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">Corticosteroid</td> <td style="padding: 13px 24px; font-weight: 500;">16mg q8h × 3 days</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">IV/PO</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #E63946; flex-shrink: 0;"></span> <span>Avoid &lt;10 wks (cleft palate risk)</span> </div> </td> </tr> <tr style="border-bottom: 1px solid #E2E8E4; font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #F8FAF7;"> <td style="padding: 13px 24px; font-weight: 700;">Mirtazapine</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">NaSSA antidepressant</td> <td style="padding: 13px 24px; font-weight: 500;">15–30mg/day</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">PO</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #6C757D; flex-shrink: 0;"></span> <span>Off-label; refractory cases</span> </div> </td> </tr> <tr style="font-family: 'Inter', sans-serif; font-size: 20px; color: #1B4332; background-color: #FFFFFF;"> <td style="padding: 13px 24px; font-weight: 700;">Thiamine (B1)</td> <td style="padding: 13px 24px; font-weight: 500; color: #4A6D5A;">Vitamin</td> <td style="padding: 13px 24px; font-weight: 500;">100–500mg/day</td> <td style="padding: 13px 24px; font-weight: 600; color: #4A6D5A;">IV</td> <td style="padding: 13px 24px; font-weight: 500;"> <div style="display: flex; align-items: center; gap: 10px;"> <span style="display: inline-block; width: 12px; height: 12px; border-radius: 50%; background-color: #1B4332; flex-shrink: 0;"></span> <span>Mandatory before IV dextrose</span> </div> </td> </tr>

<b>Ondansetron:</b> Avoid in first trimester if possible — associated with small risk of cardiac septal defects and cleft palate.

Always give <b>Thiamine BEFORE glucose/dextrose</b> to prevent Wernicke's Encephalopathy.

NUTRITION

NUTRITIONAL SUPPORT & INPATIENT CARE

Indications for Hospitalization

Failed outpatient management

Inability to tolerate ANY oral intake

>5% weight loss from pre-pregnancy weight

Severe electrolyte abnormalities

Ketonuria ≥2+ with dehydration signs

Orthostatic hypotension

Altered mental status (concern for Wernicke's)

Nutritional Escalation Ladder

Oral Refeeding

Small frequent meals, bland foods, oral rehydration, ginger, B6. Restart slowly after IV stabilization.

Enteral Nutrition

NG or NJ tube feeding. Preferred over parenteral. Continuous feeds tolerated better. Monitor for refeeding syndrome.

Total Parenteral Nutrition (TPN)

Last resort. Reserved for failure of enteral feeding. High risk: infection, thrombosis, liver disease. Requires central venous access.

Refeeding Syndrome Risk:

Monitor phosphate, magnesium, potassium when reintroducing nutrition after prolonged starvation.

PSYCHOSOCIAL

Psychosocial Impact

83%

of HG patients report significant<br>psychosocial impacts

Up to 50%

experience depression<br>and anxiety

PTSD

documented in a subset of<br>severe HG patients

Psychological Burden

<li style="margin-bottom: 12px;">Fear of eating and drinking</li><li style="margin-bottom: 12px;">Social isolation & inability to work</li><li style="margin-bottom: 12px;">Pregnancy termination considered in severe cases (15%)</li><li style="margin-bottom: 12px;">Partner and family strain</li><li style="margin-bottom: 0;">Feelings of guilt & being misunderstood by HCPs</li>

Supportive Care Strategies

<li style="margin-bottom: 12px;"><strong style="color: #1B4332; font-weight: 700;">Validate patient experience</strong> — HG is NOT psychological in origin</li><li style="margin-bottom: 12px;">Refer to perinatal mental health services</li><li style="margin-bottom: 12px;">Connect with HER Foundation & patient support networks</li><li style="margin-bottom: 12px;">Flexible work/sick leave documentation</li><li style="margin-bottom: 0;">Shared decision-making with patient</li>

<strong style="color: #74C69D; font-weight: 700;">HG has a profound psychological toll</strong> — compassionate, non-dismissive communication is part of treatment.

RESEARCH

Emerging Research & Future Directions

Recent Discoveries <span style="text-transform: none; font-weight: 400; color: #74C69D; font-size: 28px;">(2024–2026)</span>

Clinical Trials & Pipeline

<strong style="font-weight: 700; color: #1B4332;">GDF15 confirmed as primary causal driver</strong> — fetal-placental origin

<strong style="font-weight: 700; color: #1B4332;">GFRAL receptor</strong> in brainstem area postrema identified as key target

<strong style="font-weight: 700; color: #1B4332;">10 genes associated with HG</strong> identified (USC 2026 study) — 6 are newly discovered

<strong style="font-weight: 700; color: #1B4332;">Low pre-pregnancy GDF15</strong> = hypersensitivity hypothesis

<strong style="font-weight: 700; color: #1B4332;">Pre-pregnancy metformin pre-conditioning</strong> may reduce GDF15 sensitivity

Rising recognition of <strong style="font-weight: 700; color: #1B4332;">child neurodevelopmental outcomes</strong> (ADHD, autism 1.5× risk)

NGM120 — GDF15 Blocker

Phase 2 trial in UK & Australia (2025); results expected 2026. Targets GFRAL receptor to block nausea signal.

Metformin Pre-treatment

Hypothesis: raise baseline GDF15 pre-pregnancy to reduce sensitivity. Early-stage investigation.

Psychological Intervention Trials

CBT and perinatal mental health integration for HG patients.

RCOG Green-Top 2024 Update

New guidance on NVP/HG management in England.

The future of HG treatment may lie in <span style="color: #74C69D; font-weight: 700;">hormonal sensitization</span> — not just symptom suppression.

SUMMARY

KEY TAKEAWAYS

HG ≠ Morning Sickness

A serious condition with ≥5% weight loss, dehydration, and hospitalization risk.

Onset 4–6 wks, peaks 8–12 wks

May persist beyond 20 weeks in 1 in 5 patients.

GDF15 is the key driver

Fetal-placental GDF15 acting on brainstem GFRAL receptors; low maternal baseline = hypersensitivity.

Diagnose clinically

Use PUQE score; exclude differentials; check electrolytes, LFTs, TSH, urine ketones.

Stepwise management

Lifestyle → B6/doxylamine → IV fluids + thiamine → ondansetron → enteral nutrition → TPN.

Always give thiamine FIRST

Before any IV dextrose to prevent Wernicke's encephalopathy.

Don't underestimate psychosocial burden

83% of patients affected; validate symptoms, refer to mental health.

Watch the pipeline

GDF15 blocker (NGM120) in trials; genetic research reshaping our understanding.

Hyperemesis Gravidarum is a serious, evidence-based diagnosis — early recognition and treatment saves lives.

  • hyperemesis-gravidarum
  • obgyn-lecture
  • pregnancy-complications
  • medical-education
  • pathophysiology
  • maternal-health
  • clinical-guidelines
  • gdf15